Is there a broader concern about reimbursement in the space, and how is Caris differentiated?

Caris is differentiated because its assays are CDLTs, not ADLTs, and are subject to the 3-year PAMA cycle. The company submitted its PAMA data on May 1 and expects no downward adjustments, feeling confident about price stability. They are supportive of CRUSH but do not see it changing their underlying reimbursement position. “What we've managed to do is it's a little unique in that we managed to go through and we went through the CDLT process. So our codes are like CDLT, not ADLT. So we actually feel very good and we actually submitted our PAMA submission last week based on the time frame. So we feel good about it.”

How is the hiring for the ~300 sales reps progressing, and how are the new reps ramping up?

The company is on track to hit the ~300 sales rep goal, with the first wave hired and undergoing revamped training. They are already making calls, and the company feels good about the ramp-up and changes made. “Yes, we're progressing right on track of where we want to be. We changed territory size -- or territories and made them smaller. So we went from 82 to 146 territories. We'll continue to grow that amount. We have the first wave hired. We're sending them through training. They're already out making calls.”

What is the priority for MRD in the pipeline, and when can we expect a launch?

MRD is the next priority after the current product launches (ChromoSeq, MI Clarity, Caris Detect). The company will be focusing on it heavily. “Now that we have these other product launches done and behind us, MRD is the next priority. So we'll be focusing on that quite heavily.”

CAI

Caris Life Sciences (CAI) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 7, 2026

Source: earnings call transcript

Executive summary

Caris Life Sciences Q1 FY26 — Strong Revenue Growth and Profitability Driven by Molecular Profiling

Caris Life Sciences delivered a strong start to FY26, driven by robust molecular profiling revenue and continued profitability, enabling strategic investments in product pipeline and commercial expansion. The company is leveraging its financial strength to fund the Caris Detect launch and other pipeline initiatives, while navigating a sales force realignment that impacted early quarter volumes but showed strong recovery by quarter-end.

Highlights

Total revenues increased 79% year-over-year to $216 million.
Molecular profiling services revenues grew 85% year-over-year to $211 million.
Achieved positive adjusted EBITDA of $26 million and positive free cash flow of $22.5 million for the fourth consecutive quarter.
Gross margins improved to 65% on a GAAP basis, up from 47% in Q1 last year.
Refinanced $400 million debt facility, saving approximately $6 million in annual interest and extending maturity to April 2031.

Concerns

Pharma and research revenue decreased to $5.4 million from $6.8 million in Q1 2025, though expected to flow through later in the year.
Q1 completed cases were modestly below initial expectations due to timing and sales realignment, though activations improved sequentially.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year volume growth - Tissue	low teens high materiality	FY26	High
Full-year volume growth - Blood	high 50s to low 60s high materiality	FY26	High
Full-year total revenue	reconfirmed high materiality	FY26	High
Q2 sequential volume growth	10% medium materiality	Q2 · FY26	High
Q2 total revenue growth	32% medium materiality	Q2 · FY26	High
Q2 CapEx	$30 million medium materiality	Q2 · FY26	High
Q2 Operating Expenses	over $140 million medium materiality	Q2 · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Molecular Profiling Services Strong performance driven by increased volumes and improved ASPs, benefiting from the MI Cancer Seek launch and effective market access. Sales realignment in January led to sequential improvement in activations in February and March. Clinical case volumes: 52,800 (up 15% YoY)Tissue cases: 43,600Caris Assure cases: 9,200Clinical ASP increase: 61%Tissue ASP: >$4,300 (up 70%)Blood ASP: <$2,500 (up 14%)MI Cancer Seek volume contribution: >75% of tissue volume in Q1MI Cancer Seek covered lives: >225 millionCaris Assure volume growth: 58% YoY (up 7% sequentially)Orders submitted electronically: >70%Physicians using EMR integrations: >3,000	$211 million	85%	—	—
Pharma and Research Revenue was lower year-over-year due to deliverable movement of Discovery and data businesses under contract, with revenue expected to flow through over the balance of the year, supported by improved contract activity.	$5.4 million	-20.6% (vs $6.8 million in Q1 2025)	—	—

CAI operating KPIs by quarter

CAI operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2025 Q4 FY25	This call Mar 2026 Q1 FY26	Jun 2026 Q2 FY26	Change vs prior quarter
Covered lives MI Cancer Seek	225M+ The key driver for tissue was obviously the impact from our FDA approval and the subsequent increase in pricing and the benefits we saw through contract, where we have now surpassed over 225 million covered lives from MI Cancer Seek. Source: earnings call transcript	225M+ At this point, we're above $225 million covered lives for MI Cancer Seek, which we expect to continue to increase throughout the course of this year, and the assay represented more than 75% of our tissue volume in Q1. Source: earnings call transcript	~239.5M With regard to covered lives that now stands at approximately $239.5 million for MI Cancer Seq and $131.9 million for Care Assure and is a testament to the great work by our market access teams as we continue to see improvements across the payer landscape. Source: earnings call transcript	—
Procedures	—	52.8K In the first quarter, we completed 52,800 cases, up 15% year-over-year. Source: earnings call transcript	59.2K We added roughly 6,400 cases in the quarter, a record for sequential case additions that led us to 59,200 cases. Source: earnings call transcript	+12.1%
Procedures Tissue	—	~43.6K For Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases. Source: earnings call transcript	~48.3K With respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially. Source: earnings call transcript	—
Procedures Caris Assure	—	~9,200 For Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases. Source: earnings call transcript	10.7K With respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

Product	Type	Timeline
Caris ChromoSeq	launch	April 1, 2026
Caris MI Clarity	launch	—
Caris Detect	launch	Q2 FY26

Deals & partnerships

Blue Owl and Blackstone Refinancing of credit facility $400 million extended to April 2031 (3 years from Jan 2028)

New debt facility offers many advantages, providing additional strategic flexibility.

Everlywell Commercial launch partner for Caris Detect

Caris Detect multi-cancer early detection is getting ready for commercial launch with Everlywell, with plans to add additional channel partners.

Risks & headwinds

Sales force realignment impact on Q1 volumes Q1 FY26

Q1 completed cases modestly below initial expectations; January was a transition month.

Mitigation:Activations in February and March grew ~20% YoY, reinforcing demand. Expect 10% sequential volume growth in Q2 as timing gap normalizes and realignment benefits flow through.

Pharma and research revenue timing Q1 FY26

$5.4 million in Q1 FY26 vs $6.8 million in Q1 FY25

Mitigation:Revenue delta is due to deliverable movement of Discovery and data businesses under contract, expected to flow through over the balance of the year, supported by improved contract activity.

What to watch in Q2 FY26

Q2 sequential volume growth

Q2 FY26

Current Q1 completed cases: 52,800

Target Over 58,000 cases (10% sequential growth)

Why it matters

Verifies the effectiveness of the sales force realignment and the underlying demand trajectory, crucial for full-year guidance achievement.

So what our expectation is now for Q2 is, over 58,000 cases, which would be a 10% sequential growth from Q1.

Find out whether CAI delivers this. Inve re-checks your case every morning.

Q&A highlights

What was the impact of sales realignment on tissue volumes, and how confident are you in achieving the 20% volume growth target given the Q1 start?

The sales realignment caused a slower start in January, but tissue volumes improved significantly in February and March. The company is confident in achieving low teens tissue growth and high 50s to low 60s blood growth for the full year, supported by the strong exit rate from Q1.

“Yes. And one of the reasons why we also disclosed kind of the exit rate on the completions for February and March is what also gives us confidence. You can see based on those numbers, like we've improved dramatically on the tissue front from where we were running on a monthly rate last year with over 15,500 for kind of on average for February and March. So we believe that continued trend is going to benefit us as we go into Q2. So we feel good about the low teens guidance.”

asked by Alexa Chan · answered by Unknown Executive

2 min read 6 chapters

Detailed narrative

Molecular Profiling Performance and ASP Growth

Caris's molecular profiling business was the primary driver of Q1 FY26 revenue, growing 85% year-over-year to $211 million. This growth was fueled by a 15% increase in clinical case volumes and a 61% increase in average selling price (ASP) for comprehensive profiling tests.

Tissue ASP rose 70% to over $4,300, and blood ASP increased 14% to just under $2,500, reflecting successful market access and billing efforts, particularly from the MI Cancer Seek launch.

Sales Force Realignment and Volume Acceleration

The company completed a significant sales team realignment in January 2026, expanding territories from 82 to 146 and building out the field organization. While January was a transition month, activations in February and March grew approximately 20% year-over-year, reinforcing demand and supporting a quarterly exit run rate of roughly 56,000 completed cases. This momentum is expected to drive sequential volume growth of 10% in Q2.

Caris Detect Achieve 1 Data Readout

The final readout for the Achieve 1 study for Caris Detect demonstrated a 60.3% Stage 1 and Stage 2 sensitivity with 99.2% asymptomatic specificity across a 3,014-subject high-risk cohort. Sensitivity increased with stage, from 56.8% in Stage 1 to 98.6% in Stage 4.

The results were generated using only one of nine potential pillars, indicating future improvement potential. A beta launch has commenced, with commercial launch planned for Q2 with Everlywell.

New Product Launches and Pipeline Progress

Caris launched two new products: Caris ChromoSeq, a therapy selection asset for hematological cancers using whole genome technology, and Caris MI Clarity, a prognostic test for breast cancer recurrence risk using digital pathology. The pipeline also includes progress in MRD (minimal residual disease) solutions, with tumor-naive (colorectal cancer focus) and tumor-informed (pan-tumor) developments underway. MRD is identified as the next key priority after current launches.

Financial Strength and Capital Allocation

Caris maintained strong financial discipline, achieving positive adjusted EBITDA ($26 million) and free cash flow ($22.5 million) for the fourth consecutive quarter. Cash on hand increased to over $825 million. The company refinanced its $400 million debt facility, reducing annual interest costs by $6 million and extending maturity to April 2031, with an additional $300 million delayed draw term loan for strategic acquisitions.

This financial strength supports ongoing investments in the product pipeline and commercial expansion.

Reimbursement Framework and PAMA

Management clarified its reimbursement framework, stating that both MI Cancer Seek and Caris Assure assays are Clinical Diagnostic Laboratory Tests (CDLTs), not Advanced Diagnostic Laboratory Tests (ADLTs). This means they are reported under PAMA, with data submitted on May 1. The company does not expect any downward adjustments from this process and supports broader CRUSH efforts, believing its pricing is stable.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.